Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.

• A Phase 1/2 study on the effects of LOXO-292 (study drug) in patients with advanced solid tumors. Recruitment ended
  2023-507702-13-00 7 2017-09-22

Showing 1–1 of 1 trials